Cohance Lifesciences Ltd to sell CR Bio assets to Chromo Laboratories India Pvt Ltd

Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited) has entered into an agreements with Chromo Laboratories India Private Limited for the sale of the assets pertaining to its standalone Clinical Research and Bio-analytical unit ('CR Bio'), for a consideration of ₹16 crore. The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations.

Shares of Cohance Lifesciences Limited was last trading in BSE at Rs. 986.00 as compared to the previous close of Rs. 989.45. The total number of shares traded during the day was 4128 in over 297 trades.

The stock hit an intraday high of Rs. 996.85 and intraday low of 976.90. The net turnover during the day was Rs. 4069669.00.

Source : Equity Bulls

Keywords

CohanceLifesciences INE03QK01018 Pharmaceuticals Agreement ChromoLaboratoriesIndia CRBio